Join DDW and Synthego for this free exclusive event today at 3pm GMT.
Kevin Holden, Ph.D, Head of Science, Synthego will explain how the company’s engineered cell libraries enable screening more widely and efficiently to increase the pace and impact of target discovery.
Register now to hear speakers Kevin Holden and Teddy Lin, Associate Director, Commercial Strategy, Synthego.
CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have.
What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect your CRISPR library?
